CTOs on the Move

VelosBio

www.velosbio.com

 
VelosBio Inc. is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, ROR1-directed therapeutics to transform the lives of patients with cancer. Its lead candidate, VLS-101, is a ROR1-directed ADC being developed for patients with hematologic and solid tumor malignancies. The company is developing a broad pipeline of therapeutics targeting ROR1 in oncologic indications with high unmet medical need.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.velosbio.com
  • 11045 Roselle Street Suite 130
    San Diego, CA USA 92121
  • Phone: 858.461.6666

Executives

Name Title Contact Details

Funding

VelosBio raised $58M on 10/01/2018
VelosBio raised $137M on 07/08/2020

Similar Companies

Third Wave Technologies

Third Wave Technologies, Inc. is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Agensys

Agensys is a Santa Monica, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Evommune

Evommune is a clinical stage biotechnology company dedicated to the development of transformative medicines for inflammatory diseases. We are leveraging our innovative, tissue-based approach to advance insights and accelerate the development of these transformative therapies. Evommune is led by a successful and experienced leadership team focused on building a robust pipeline of unique therapies that help patients with chronic inflammatory diseases.

Reneo Pharmaceuticals

Reneo is a clinical stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases. Many of these diseases are associated with deficits in cellular metabolism and energy production. Our goal is to improve daily function and quality of life of patients suffering from these diseases, most specifically, by improving how their mitochondria work, preserving muscle function and preventing muscle injury, weakness and wasting.

Agena Bioscience

Agena Bioscience’s scalable MassARRAY System enables one day assay turnaround times on a wide variety of targeted genetic tests.